Sugi Predict

Sugi Predict / Compounds / SCHEMBL2293500

SCHEMBL2293500

SCHEMBL2293500

Cc1cccc(C)c1Nc1c(-c2ccc(Cl)cc2OCC(N)=O)nc2ccc(F)cn12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 12/20 0.47
▸ MAPT P10636 7/20 0.47
▸ TRPA1 O75762 1/20 0.41
▸ TP53 P04637 7/20 0.40
▸ POLB P06746 2/20 0.40
▸ GABRD O14764 1/20 0.39
▸ GABRB1 P18505 1/20 0.39
▸ GABRA4 P48169 1/20 0.39
▸ ATM Q13315 3/20 0.38
▸ SMN1; SMN2 Q16637 4/20 0.37
▸ LMNA P02545 1/20 0.37
▸ GLA P06280 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ ALDH1A1 P00352 2/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ CYP1A2 P05177 1/20 0.35
▸ CYP2D6 P10635 1/20 0.35
▸ CYP2C9 P11712 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ CYP2C19 P33261 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2289516 0.93 GAA (0.47) GAAMAPTTRPA1TP53POLB
SCHEMBL2289236 0.93 TRPA1 (0.45) GAAMAPTTRPA1TP53POLB
SCHEMBL2290086 0.92 GAA (0.43) GAAMAPTTRPA1TP53POLB
SCHEMBL2292255 0.92 GAA (0.49) GAAMAPTTRPA1TP53POLB
SCHEMBL2289462 0.90 GAA (0.47) GAAMAPTTRPA1TP53POLB
SCHEMBL2287174 0.90 GAA (0.44) GAAMAPTTRPA1TP53POLB
SCHEMBL2290123 0.89 GAA (0.43) GAAMAPTTRPA1TP53POLB
SCHEMBL2287600 0.88 TRPA1 (0.45) GAAMAPTTRPA1TP53POLB
SCHEMBL2287300 0.88 TRPA1 (0.43) GAAMAPTTRPA1TP53POLB
SCHEMBL2291158 0.87 TRPA1 (0.43) GAAMAPTTRPA1TP53POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2032571-B1 3 -AMINO-IMIDAZO[1, 2-A]PYRIDINE DERIVATIVES AS SGLT INHIBITORS MERCK PATENT GMBH (DE) 2014-12-03 — — EP claimed
US-8258151-B2 3-aminoimidazo [1,2-A] pyridine derivatives as SGLT inhibitors MERCK PATENT GMBH (DE) 2012-09-04 — — US claimed
US-20110195991-A1 3-AMINOIMIDAZO [1,2-A] PYRIDINE DERIVATIVES AS SGLT INHIBITORS MERCK PATENT GESELLSCHAFT (DE) 2011-08-11 — — US claimed
EP-2032571-B1 3 -AMINO-IMIDAZO[1, 2-A]PYRIDINE DERIVATIVES AS SGLT INHIBITORS MERCK PATENT GMBH (DE) 2014-12-03 — — EP disclosed
US-8258151-B2 3-aminoimidazo [1,2-A] pyridine derivatives as SGLT inhibitors MERCK PATENT GMBH (DE) 2012-09-04 — — US disclosed
US-20110195991-A1 3-AMINOIMIDAZO [1,2-A] PYRIDINE DERIVATIVES AS SGLT INHIBITORS MERCK PATENT GESELLSCHAFT (DE) 2011-08-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110195991-A1 3-AMINOIMIDAZO [1,2-A] PYRIDINE DERIVATIVES AS SGLT INHIBITORS GLP1R, SLC5A1, SLC5A2 GAA 1202/4885MAPT 1138/4885TRPA1 1229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.